• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of celstresspringer.comThis journalToc AlertsSubmit OnlineOpen ChoiceThis Journal
Cell Stress Chaperones. Mar 2009; 14(2): 133–139.
Published online Aug 7, 2008. doi:  10.1007/s12192-008-0064-y
PMCID: PMC2727995

Polyamine compound deoxyspergualin inhibits heat shock protein-induced activation of immature dendritic cells

Abstract

Polyamine compound deoxyspergualin (DSG) is a potent immunosuppressive agent that has been applied clinically for protecting graft rejection and treatment of Wegener's granulomatosis. Though DSG can bind to heat-shock proteins (HSPs) in cells, its mechanism of immunosuppressive action remains unknown. It is widely accepted that extracellular HSPs are capable of stimulating dendritic cells (DC) through cell surface receptors, leading to DC activation and cytokine release. In this study, we examined if DSG analogs could inhibit HSP70-induced DC activation. Bone marrow derived immature mouse DCs and peripheral blood mononuclear cell-derived immature human DCs were generated and incubated with Alexa 488-labeled Hsp70 in the presence of methoxyDSG (Gus-1) that had comparable HSP70-binding affinity to DSG or DSG analog GUS-7, which had much more reduced binding affinity for HSP70. The binding of HSP70 to immature DCs was analyzed by laser microscopy and flow cytometry. HSP70-induced DC activation was assessed by TNF-α release by enzyme-linked immunosorbent assay. Binding of Hsp70 to the cell surface of immature DCs was inhibited under the presence of Gus-1, but not under the presence of Gus-7. Immature DCs were activated and released TNF-α by the stimulation with HSP70 for 12 hours; however, the HSP70-induced TNF-α release was suppressed under the presence of Gus-1, and partially suppressed under the presence of Gus-7. Similar results were observed when immature human DCs were stimulated under the same conditions. Immunosuppressive mechanism of DSG may be explained, at least in part, by the inhibition of extracellular HSP70-DC interaction and HSP70-induced activation of immature DCs.

Electronic supplementary material

The online version of this article (doi:10.1007/s12192-008-0064-y) contains supplementary material, which is available to authorized users.

Keywords: HSP70, Deoxyspergualin, Dendritic cells, Immunosuppressant

Introduction

Heat-shock proteins (HSPs) are proteins whose expression is increased when the cells are exposed to elevated temperatures or other stress. They are known to play an important role in intracellular protein quality control since they serve to assist folding, sorting, and degradation of cellular proteins, thus preventing intracellular accumulation of degenerated proteins. Recently, it was revealed that extracellular HSPs could serve as a danger signal, which activate inflammatory response and natural immunity in response to cellular injury (Manjili et al. 2005; Asea 2006; Calderwood et al. 2007). 70 kD HSP (HSP70) and 96 kD HSP (gp96) have been well documented for the mechanism of activation (Doody et al. 2004; Massa et al. 2005; Li et al. 2006; Bendz et al. 2007). HSPs are released into extracellular fluid during cell death or injury, and then bind to the surface of immune cells through cell surface receptors, such as toll-like receptor (TLR) 2, TLR4, CD91, CD40, CCR5, LOX-1, and Scavenger receptor A (Arnold-Schild et al. 1999; Delneste et al. 2002; Roelofs et al. 2006; Warger et al. 2006; Facciponte et al. 2007; Pido-Lopez et al. 2007). The extracellular HSPs can elicit cytokine releases from dendritic cells, macrophages and lymphocytes, leading to activation of innate immunity (Todryk et al. 1999; Asea et al. 2000; Asea 2006). In addition, HSPs are capable of facilitating antigen cross-presentation in dendritic cells, i.e., presentation of extracellular antigens to major histocompatibility complex (MHC) class I pathway, therefore leading to activation of adaptive immunity as well (SenGupta et al. 2004; Ueda et al. 2004; Facciponte et al. 2005; Enomoto et al. 2006; Bendz et al. 2007; Kurotaki et al. 2007). Such an unique immunopotentiative character of HSPs are now applied to vaccine adjuvants, especially in the field of cancer immunotherapy (Srivastava and Udono 1994; Tamura et al. 1997; Noessner et al. 2002; Hauser et al. 2004; Ueda et al. 2004; Wang et al. 2005).

On the other hand, immunosuppressive therapy is required in the field of organ transplantation and autoimmune diseases. Deoxyspergualine (DSG) is one of such immunosuppressive agents, which has been used after renal transplantation and for the treatment of glomerulonephritis (Amemiya 1996; Hotta et al. 1999; Kozaki et al. 1999; Amada et al. 2005; Lorenz et al. 2005). Recently, it was revealed that DSG was effective in the treatment of refractory Wegener’s granulomatosis (Schmitt et al. 2005; Erickson and Hwang 2007). Disease improvement during treatment with DSG was achieved in 70% of cases (Birck et al. 2003). In spite of the clinical efficacy of DSG, molecular mechanism of the immunosuppressive action has been still enigmatic. Nadler et al. demonstrated previously that DSG could bind to HSP70 and HSP90 (Nadler et al. 1992, 1998; Nadeau et al. 1994). They showed that DSG can suppress NF-kB signal indirectly by binding to intracellular HSP70 (Nadler et al. 1995). We have found that DSG inhibited the association of HSP70 to TAP, thus leading to inhibition of MHC class I antigen presentation (Kamiguchi et al. 2008). In the present study, we focused on the effect of DSG to immunopotentiative action of extracellular HSPs. Binding of HSP70 to the cell surface and subsequent cytokine release from dendritic cells were assessed in the presence or absence of DSG analogs that have a distinct binding affinity to HSP70. We demonstrate that immunosuppressive action of DSG is mediated, at least in part, through blocking of danger signals of HSP70.

Materials and methods

Reagents

Two distinct DSG analogs, Gus-1 (methoxyDSG) and Gus-7 (Fig. 1), were provided by Nippon Kayaku (Tokyo, Japan). DSG and Gus-1 have a high binding affinity for HSP70 (Kd = 7 μM and 4 μM, respectively), whereas Gus-7 has much reduced affinity for HSP70 (Kd = 250 μM) (Nadeau et al. 1994). Purified human Hsp70 and recombinant HSP90 were purchased from StressGen Biotech (Ann Arbor, MI). Bovine serum albumin (BSA) and phosphorylase B were purchased from Sigma-Aldrich (St. Louis, MO).

Fig. 1
Structure of DSG and two distinct DSG analogs, Gus-1 and Gus-7. Gus-1 (methoxyDSG) has high binding affinity for HSP70 (Kd = 4 μM), whereas Gus-7 has reduced binding affinity for HSP70 (Kd = 250 μM) ...

Generation of bone marrow derived dendritic cells

Bone marrow derived immature mouse DCs were generated from the femurs and tibia of 5- to 6-week-old C57BL/6 mice (CLEA Japan, Tokyo, Japan). Bone marrow cells (1 × 105/well in a 24-well plate) were incubated in a complete RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% heat inactivated fetal calf serum (GIBCO/Invitrogen, Carlsbad, CA) and 20 ng/ml GM-CSF (Endogen, Woburn, MA) for 5 days. GM-CSF-containing medium was gently replaced on day 2 and day 4.

Immature human DCs were generated from peripheral blood mononuclear cells (PBMCs) of healthy volunteers after obtaining informed consent. Briefly, PBMCs were isolated by using Lymphoprep (Nycomed, Oslo, Norway), and then separated into CD14+ cells and CD14 cells by using MACS separation system and anti-CD14 monoclonal antibody-coupled magnetic microbeads (Miltenyi Biotech, Bergish Blabach, Germany) according to the manufacturer's instruction. Immature DCs were generated from CD14+ cells in the plastic flask by culturing in AIM-V medium (GIBCO-Invitrogen Japan) supplemented with 10% human serum, HEPES (10 mmol/L), 2-mercaptoethanol (50 μmol/L), granulocyte macrophage colony-stimulating factor (100 ng/mL), and IL-4 (1,000 units/mL) for 7 days.

Detection of fluorescence-labeled Hsp70 on the cell surface of DCs

HSP70 and phosphorylase B were labeled with Alexa Fluor 488 by using Alexa Fluor 488 Protein Labeling Kit (Invitrogen, Japan) according to the manufacturer’s instruction (Kurotaki et al. 2007). DCs were incubated with 10 μg/ml of Alexa-labeled Hsp70 or Alexa-labeled phosphorylase B in the presence of Gus-1 or Gus-7 (10 μg/ml). DCs were then washed twice with ice-cold phosphate-buffered saline (PBS), fixed with ice-cold 1% formaldehyde PBS, and analyzed by flow cytometry (FACScan, Becton Dickinson, Mountain View, CA) or laser microscopy (Olympus, Japan).

TNF-α release assay

Dendritic cells were pulsed with the indicated concentrations of Hsp70 in the presence of Gus-1 or Gus-7 (10 μg/ml). After incubation for 12 hours, the concentration of TNF-α released into the culture supernatant was quantified by using mouse TNF ELISA kit (Endogen, Woburn, fMA).

Results

DSG inhibits the binding of HSP70 to the cell surface of immature DCs

Purified HSP70 and phosphorylase B were labeled with Alexa Fluor 488 and then incubated with immature mouse DCs for 30 min on ice. Laser microscopic analysis revealed that HSP70 was bound to the cell surface of DCs with a dot-like pattern, whereas phosphorylase B was not (Fig. 2A). Then, the fluorescence intensity was analyzed by flow cytometer in the presence or absence of Gus-1 or Gus-7 (10 μg/mL). As shown in Fig. 2B, the fluorescence intensity of HSP70-pulsed DCs was not changed between PBS and Gus-7 (left panel), whereas it was decreased in the presence of Gus-1 (right panel). These data indicate that Gus-1, but not Gus-7 could inhibit the binding of HSP70 to the cell surface of DCs.

Fig. 2
DSG inhibits the binding of HSP70 to the cell surface of immature DCs. Purified HSP70 and phosphorylase B were labeled with Alexa Fluor 488 and then incubated with immature DCs for 30 min on ice. After washing twice with ice-cold PBS, cells were ...

HSP70 stimulation induces TNF-α release of immature DCs

Next, we examined if HSP70 can activate immature DCs. As an activation index, the level of TNF-α release was assessed by ELISA. The indicated concentrations of HSP70 or BSA were pulsed to immature mouse DCs (1 × 105 cells/well), and TNF-α concentration of culture supernatant was quantified after 12-hour incubation. Stimulation with HSP70 clearly induced the release of TNF-α from DCs, while BSA failed under the same condition (Fig. 3A). Time course of TNF-α release indicated that it reached to almost the peak level after 12 hours incubation (supplemental figure). We also examined if HSP90 was capable of stimulating human DCs. As shown in Fig. 3B, HSP90 has just minimal effect on the immature human DCs. As a positive control, the same numbers of DCs were stimulated with the indicated concentration of lipopolysaccharide (LPS). Examination of the LPS concentration in the HSP70 used in this study revealed approximately 25 pg/ml (Mitsubishi Chemical Medience, Japan). These data indicate that HSP70 may have higher stimulatory activity to immature DCs as compared with HSP90, as far as TNF-α release is assessed as an activation index. IL-12 release assay resulted in the similar results (data not shown).

Fig. 3
HSP70 stimulation induces TNF-α release of immature DCs. The indicated concentrations of HSP70 or BSA were pulsed to immature mouse DCs (50,000 cells/well), and TNF-α concentration of culture supernatant was quantified after 12 hours ...

DSG inhibits the HSP70-induced TNF-α release of immature DCs

We then examined if DSG analogs could inhibit the HSP70-induced activation of immature DCs. The indicated concentrations of HSP70 or BSA were pulsed to immature mouse DCs (5 × 104 cells/well) in the presence or absence of Gus-1 or Gus-7 (10 μg/ml). Following incubation for 12 hours, TNF-α concentration of culture supernatant was quantified. It was shown that TNF-α release was inhibited to almost the half level of PBS control in the presence of Gus-1, whereas it was partially inhibited in the presence of Gus-7 (Fig. 4A). Similar results were obtained when immature human DCs (1 × 105 cell /well) were pulsed with HSP70 in the presence or absence of Gus-1 or Gus-7 (10 μg/ml), though the significant difference was observed only in the case of 10 μg/ml pulsation of HSP70 (Fig. 4B).

Fig. 4
DSG inhibits the HSP70-induced TNF-α release of immature DCs. The indicated concentrations of HSP70 or BSA were pulsed to immature mouse DCs (5 × 104 cells/well) in the presence or absence of Gus-1 or Gus-7 (10 μg/ml) ...

In order to rule out the possibility that the suppressive action of DSG might be mediated through intracellular molecules, such as intracellular HSP70 and HSP90, immature mouse DCs were pre-incubated for 2 hours with Gus-1 or Gus-7 (10 μg/ml), then washed twice and pulsed with 5 μg/ml of HSP70 in the presence or absence of Gus-1 (10 μg/ml). The data show that pre-incubation did not have any effect on the HSP70-induced TNF-α release, indicating that the suppressive action of DGS might be resulted from the binding of DSG to extracellular HSP70 (Fig. 4C).

DSG inhibits the HSP70-induced maturation of DCs

We next examined if DSG analogs could affect the HSP70-induced maturation of immature DCs. Immature mouse DCs were incubated for 12 hours in the presence or absence of 10 μg/ml of HSP70. In some cases, Gus-1 or Gus-7 (10 μg/ml) was added into the culture. Following incubation for 12 hours, cell surface level of CD80 was analyzed by flow cytometry as a DC maturation index. It was shown that incubation of immature DCs with HSP70 increased the CD80 levels, indicating that HSP70 induced DC maturation. The HSP70-induced DC maturation was suppressed in the presence of Gus-1 (Fig. 5A), but not in the presence of Gus-7 (Fig. 5B). The other maturation markers such as CD86 and CD40 were not changed after the stimulation with HSP70. The data imply that HSP70-induced partial maturation of immature DCs detected by CD80 expression was inhibited in the presence of DSG.

Fig. 5
HSP70 stimulation induces up-regulation CD80 level of immature DCs. Immature mouse DC were stimulated with 10 μg/ml of HSP70 or BSA, cultured for 12 hours and examined for the cell surface level of CD80 by flow cytometry. In A ...

Discussion

In the present study, we demonstrated for the first time that DSG analogs had suppressive activity to the so-called “danger signals.” A variety of cell injuries damage the cell membrane, leading to the release of intracellular HSPs into extracellular fluids. The released HSPs are bound to immunostimulatory molecules, such as TLRs (TLR2 and 4), CD40 and CCR5, or captured by scavenger receptor families, such as CD91, LOX-1 and SR-A (Arnold-Schild et al. 1999; Delneste et al. 2002; Lipsker et al. 2002; Roelofs et al. 2006; Warger et al. 2006; Facciponte et al. 2007; Pido-Lopez et al. 2007). The former stimulation induces release of inflammatory cytokines, thus activating innate immune responses (Asea et al. 2000). On the other hand, the latter stimulation induces endocytosis of HSPs with HSP-bound antigenic proteins or peptides, then facilitating the cross-presentation of the HSP-bound antigens and acquired immunity (Noessner et al. 2002; SenGupta et al. 2004). Though the mechanism of the HSP-mediated efficient cross-presentation remains largely unknown, we have reported previously that HSP70 and HSP90 could facilitate the transfer of endosomal antigens to recycled endosomes that contain empty MHC class I molecules (Ueda et al. 2004; Kurotaki et al. 2007). In addition, HSP90 could also assist the transfer of endosomal antigens into cytosol by unknown mechanism, and facilitate the proteasomal degradation of the antigens (Kurotaki et al. 2007). In the present study, we clearly demonstrate that DSG was capable of inhibiting the binding of extracellular HSP70 to the cell surface of DCs. Therefore, it is highly likely that DSG inhibits not only innate immune responses but also acquired immune responses.

Deoxyspergualin has been used clinically as an immunosuppressive agent after organ transplantation (Nomura et al. 1998). Moreover, most recent clinical trials in Germany demonstrated that it is effective to refractory autoimmune vasculitis including Wegener's granulomatosis (Schmitt et al. 2005; Erickson and Hwang 2007). Concerning the mechanism of immunosuppressive and anti-inflammatory actions of DSG, there are several reports that explain the molecular mechanism (Amemiya 1996). Nadler et al. demonstrated that the intracellular targets of DSG were HSP70 and HSP90 and suggested that suppression of NF-kB signal might be involved in the anti-inflammatory reaction (Nadler et al. 1995). However, there are some controversial data as to the hypothesis. Kawada et al. showed that DSG inhibits AKT signals and phosphatidylcholine synthesis (Kawada et al. 2002). Waaga et al. reported that DSG could down-regulate the expression of MHC class II molecules, though the precise mechanism remained unknown (Waaga et al. 1996). Our group showed that intracellular HSP70 might be a target of DSG, and the binding of DSG to HSP70 disrupted the association of cytosolic antigen-bound HSP70 with TAP, leading to inhibition of TAP-mediated peptide transfer into the endoplasmic reticulum and down-regulation of cell surface MHC class I levels (Kamiguchi et al. 2008). In the present study, we demonstrated that the target molecules of DSG might be not only intracellular HSPs but also extracellular HSPs, which mediate the so-called “danger signals”. It is expected that DSG might be effective in the treatment of other refractory inflammatory or autoimmune diseases, such as Behcet disease, inflammatory bowel diseases, glomerulonephritis, and systemic inflammatory response syndrome, which are considered to be broken out by dysregulated activation of danger signals.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1(46K, gif)

Time course of HSP70-induced TNF-α release of mouse immature DCs. Ten micrograms per milliliter of HSP70 or BSA were pulsed to immature mouse DCs (50,000 cells/well), and TNF-α concentration of culture supernatant was quantified after the indicated incubation time. (GIF 46.3 kb)

Acknowledgment

We are grateful to Dr. Hisami Ikeda of Hokkaido Red Cross Blood Center for his generous help in our study. This study was supported in part by a grant-aid for Clinical Cancer Research from the Ministry of Health, Labor and Welfare of Japan and a grant-aid from Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

  • Amada N, Okazaki H, Sato T, Ohashi Y, Kikuchi H. Deoxyspergualin prophylaxis with tacrolimus further improves long-term graft survival in living-related renal-transplant recipients transfused with donor-specific blood. Transplant Proc. 2005;37:927–929. doi: 10.1016/j.transproceed.2004.12.289. [PubMed] [Cross Ref]
  • Amemiya H. 15-Deoxyspergualin: a newly developed immunosuppressive agent and its mechanism of action and clinical effect: a review. Japan Collaborative Transplant Study Group for NKT-01. Artif Organs. 1996;20:832–835. doi: 10.1111/j.1525-1594.1996.tb04555.x. [PubMed] [Cross Ref]
  • Arnold-Schild D, Hanau D, Spehner D, Schmid C, Rammensee HG, Salle H, Schild H. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol. 1999;162:3757–3760. [PubMed]
  • Asea A. Initiation of the immune response by extracellular Hsp72: chaperokine activity of Hsp72. Curr Immunol Rev. 2006;2:209–215. doi: 10.2174/157339506778018514. [PMC free article] [PubMed] [Cross Ref]
  • Asea A, Kabingu E, Stevenson MA, Calderwood SK. HSP70 peptide-bearing and peptide-negative preparations act as chaperokines. Cell Stress Chaperones. 2000;5:425–431. doi: 10.1379/1466-1268(2000)005<0425:HPBAPN>2.0.CO;2. [PMC free article] [PubMed] [Cross Ref]
  • Bendz H, Ruhland SC, Pandya MJ, Hainzl O, Riegelsberger S, Brauchle C, Mayer MP, Buchner J, Issels RD, Noessner E. Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling. J Biol Chem. 2007;282:31688–31702. doi: 10.1074/jbc.M704129200. [PubMed] [Cross Ref]
  • Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grunke M, Peter HH, Kalden JR, Gobel U, Drexler JM, Hotta O, Nowack R, Woude FJ. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol. 2003;14:440–447. doi: 10.1097/01.ASN.0000048716.42876.14. [PubMed] [Cross Ref]
  • Calderwood SK, Mambula SS, Gray PJ., Jr. Extracellular heat shock proteins in cell signaling and immunity. Ann N Y Acad Sci. 2007;1113:28–39. doi: 10.1196/annals.1391.019. [PubMed] [Cross Ref]
  • Delneste Y, Magistrelli G, Gauchat J, Haeuw J, Aubry J, Nakamura K, Kawakami-Honda N, Goetsch L, Sawamura T, Bonnefoy J, Jeannin P. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity. 2002;17:353–362. doi: 10.1016/S1074-7613(02)00388-6. [PubMed] [Cross Ref]
  • Doody AD, Kovalchin JT, Mihalyo MA, Hagymasi AT, Drake CG, Adler AJ. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+T cell effector function. J Immunol. 2004;172:6087–6092. [PMC free article] [PubMed]
  • Enomoto Y, Bharti A, Khaleque AA, Song B, Liu C, Apostolopoulos V, Xing PX, Calderwood SK, Gong J. Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells. J Immunol. 2006;177:5946–5955. [PubMed]
  • Erickson VR, Hwang PH. Wegener's granulomatosis: current trends in diagnosis and management. Curr Opin Otolaryngol Head Neck Surg. 2007;15:170–176. [PubMed]
  • Facciponte JG, MacDonald IJ, Wang XY, Kim H, Manjili MH, Subjeck JR. Heat shock proteins and scavenger receptors: role in adaptive immune responses. Immunol Invest. 2005;34:325–342. doi: 10.1081/IMM-200064505. [PubMed] [Cross Ref]
  • Facciponte JG, Wang XY, Subjeck JR. Hsp110 and Grp170, members of the Hsp70 superfamily, bind to scavenger receptor – a and scavenger receptor expressed by endothelial cells-I. Eur J Immunol. 2007;37:2268–2279. doi: 10.1002/eji.200737127. [PubMed] [Cross Ref]
  • Hauser H, Shen L, Gu QL, Krueger S, Chen SY. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther. 2004;11:924–932. doi: 10.1038/sj.gt.3302160. [PubMed] [Cross Ref]
  • Hotta O, Furuta T, Chiba S, Yusa N, Taguma Y. Immunosuppressive effect of deoxyspergualin in proliferative glomerulonephritis. Am J Kidney Dis. 1999;34:894–901. doi: 10.1016/S0272-6386(99)70048-X. [PubMed] [Cross Ref]
  • Kamiguchi K, Torigoe T, Fujiwara O, Ohshima S, Hirohashi Y, Sahara H, Hirai I, Kohgo Y, Sato N. Disruption of the association of 73 kD heat shock cognate protein with transporters associated with antigen processing (TAP) decreases TAP-dependent translocation of antigenic peptides into the endoplasmic reticulum. Microbiol Immunol. 2008;52:94–106. doi: 10.1111/j.1348-0421.2008.00017.x. [PubMed] [Cross Ref]
  • Kawada M, Masuda T, Ishizuka M, Takeuchi T. 15-Deoxyspergualin inhibits Akt kinase activation and phosphatidylcholine synthesis. J Biol Chem. 2002;277:27765–27771. doi: 10.1074/jbc.M200318200. [PubMed] [Cross Ref]
  • Kozaki K, Kozaki M, Nagao T. Usefulness of 15-deoxyspergualin for rejection in renal transplantation. Transplant Proc. 1999;31:1138–1139. doi: 10.1016/S0041-1345(98)01937-X. [PubMed] [Cross Ref]
  • Kurotaki T, Tamura Y, Ueda G, Oura J, Kutomi G, Hirohashi Y, Sahara H, Torigoe T, Hiratsuka H, Sunakawa H, Hirata K, Sato N. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J Immunol. 2007;179:1803–1813. [PubMed]
  • Li D, Li H, Zhang P, Wu X, Wei H, Wang L, Wan M, Deng P, Zhang Y, Wang J, Liu Y, Yu Y. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity. Eur J Immunol. 2006;36:1324–1336. doi: 10.1002/eji.200535490. [PubMed] [Cross Ref]
  • Lipsker D, Ziylan U, Spehner D, Proamer F, Bausinger H, Jeannin P, Salamero J, Bohbot A, Cazenave JP, Drillien R, Delneste Y, Hanau D, Salle H. Heat shock proteins 70 and 60 share common receptors which are expressed on human monocyte-derived but not epidermal dendritic cells. Eur J Immunol. 2002;32:322–332. doi: 10.1002/1521-4141(200202)32:2<322::AID-IMMU322>3.0.CO;2-0. [PubMed] [Cross Ref]
  • Lorenz HM, Grunke M, Wendler J, Heinzel PA, Kalden JR. Safety of 15-deoxyspergualin in the treatment of glomerulonephritis associated with active systemic lupus erythematosus. Ann Rheum Dis. 2005;64:1517–1519. doi: 10.1136/ard.2005.035329. [PMC free article] [PubMed] [Cross Ref]
  • Manjili MH, Park J, Facciponte JG, Subjeck JR. HSP110 induces “danger signals” upon interaction with antigen presenting cells and mouse mammary carcinoma. Immunobiology. 2005;210:295–303. doi: 10.1016/j.imbio.2005.04.002. [PubMed] [Cross Ref]
  • Massa C, Melani C, Colombo MP. Chaperon and adjuvant activity of hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigens. Cancer Res. 2005;65:7942–7949. [PubMed]
  • Nadeau K, Nadler SG, Saulnier M, Tepper MA, Walsh CT. Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. Biochemistry. 1994;33:2561–2567. doi: 10.1021/bi00175a027. [PubMed] [Cross Ref]
  • Nadler SG, Dischino DD, Malacko AR, Cleaveland JS, Fujihara SM, Marquardt H. Identification of a binding site on Hsc70 for the immunosuppressant 15-deoxyspergualin. Biochem Biophys Res Commun. 1998;253:176–180. doi: 10.1006/bbrc.1998.9775. [PubMed] [Cross Ref]
  • Nadler SG, Eversole AC, Tepper MA, Cleaveland JS. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Ther Drug Monit. 1995;17:700–703. doi: 10.1097/00007691-199512000-00026. [PubMed] [Cross Ref]
  • Nadler SG, Tepper MA, Schacter B, Mazzucco CE. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science. 1992;258:484–486. doi: 10.1126/science.1411548. [PubMed] [Cross Ref]
  • Noessner E, Gastpar R, Milani V, Brandl A, Hutzler PJ, Kuppner MC, Roos M, Kremmer E, Asea A, Calderwood SK, Issels RD. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol. 2002;169:5424–5432. [PubMed]
  • Nomura Y, Tomikawa S, Beck Y, Nishimura Y, Meigata K, Ando Y, Kikuchi K. Effect of deoxyspergualin on acute and chronic rejection in renal transplantation. Transplant Proc. 1998;30:3580–3581. doi: 10.1016/S0041-1345(98)01144-0. [PubMed] [Cross Ref]
  • Pido-Lopez J, Whittall T, Wang Y, Bergmeier LA, Babaahmady K, Singh M, Lehner T. Stimulation of cell surface CCR5 and CD40 molecules by their ligands or by HSP70 up-regulates APOBEC3G expression in CD4(+) T cells and dendritic cells. J Immunol. 2007;178:1671–1679. [PubMed]
  • Roelofs MF, Boelens WC, Joosten LA, Abdollahi-Roodsaz S, Geurts J, Wunderink LU, Schreurs BW, Berg WB, Radstake TR. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol. 2006;176:7021–7027. [PubMed]
  • Schmitt WH, Birck R, Heinzel PA, Gobel U, Choi M, Warnatz K, Peter HH, Woude FJ. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant. 2005;20:1083–1092. doi: 10.1093/ndt/gfh763. [PubMed] [Cross Ref]
  • SenGupta D, Norris PJ, Suscovich TJ, Hassan-Zahraee M, Moffett HF, Trocha A, Draenert R, Goulder PJ, Binder RJ, Levey DL, Walker BD, Srivastava PK, Brander C. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J Immunol. 2004;173:1987–1993. [PubMed]
  • Srivastava PK, Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol. 1994;6:728–732. doi: 10.1016/0952-7915(94)90076-0. [PubMed] [Cross Ref]
  • Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 1997;278:117–120. doi: 10.1126/science.278.5335.117. [PubMed] [Cross Ref]
  • Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A, Vile RG. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol. 1999;163:1398–1408. [PubMed]
  • Ueda G, Tamura Y, Hirai I, Kamiguchi K, Ichimiya S, Torigoe T, Hiratsuka H, Sunakawa H, Sato N. Tumor-derived heat shock protein 70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity. Cancer Sci. 2004;95:248–253. doi: 10.1111/j.1349-7006.2004.tb02211.x. [PubMed] [Cross Ref]
  • Waaga AM, Fandrich F, Krzymanski M, Eckstein V, Herwartz C, Muller-Ruchholtz W, Russell ME. 15-deoxyspergualin downregulates MHC class II antigen expression and cell migration in models of graft-versus-host and host-versus-graft disease. Transplant Proc. 1996;28:2515–2517. [PubMed]
  • Wang XH, Qin Y, Hu MH, Xie Y. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol Immunother. 2005;54:971–980. doi: 10.1007/s00262-005-0662-9. [PubMed] [Cross Ref]
  • Warger T, Hilf N, Rechtsteiner G, Haselmayer P, Carrick DM, Jonuleit H, Landenberg P, Rammensee HG, Nicchitta CV, Radsak MP, Schild H. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem. 2006;281:22545–22553. doi: 10.1074/jbc.M502900200. [PubMed] [Cross Ref]

Articles from Cell Stress & Chaperones are provided here courtesy of Cell Stress Society International
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...